Full Text View
Tabular View
No Study Results Posted
Related Studies
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
This study is currently recruiting participants.
Study NCT00630344   Information provided by Dana-Farber Cancer Institute
First Received: February 28, 2008   Last Updated: January 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
RAD001
Bicalutamide
Additional drug interventions recognized in this trial
Androgens
Everolimus
More general drug interventions related to this trial
Androgen Antagonists
Antineoplastic Agents
Hormone Antagonists
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services